The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

In the US, 1 in 7 adults are experiencing some type of chronic kidney disease caused by diabetes. The new approval therefore allows doctor to prescribe Ozempic to lower the risk of kidney failure, ...

Ozempic becomes the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease The Food and Drug ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

A popular diabetes drug just got a major new approval -- and it could be a game-changer for millions of Americans a ...

Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval ...

The FDA's move may change how doctors treat chronic kidney disease, which, according to Ozempic maker Novo Nordisk, affects around 37 million Americans and is one of the leading causes of death in the ...

Singer Avery has been diagnosed with a condition that's thought to affect over 10 million Americans after she began using ...

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...

Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...